Merck KGaA (FRA:MRK) received a €116.00 ($136.47) price target from equities researchers at Berenberg Bank in a research note issued on Thursday. The firm presently has a “buy” rating on the healthcare company’s stock. Berenberg Bank’s price target suggests a potential upside of 29.46% from the stock’s previous close.

Several other equities analysts have also recently issued reports on the stock. UBS Group AG set a €120.00 ($141.18) price target on shares of Merck KGaA and gave the company a “buy” rating in a research report on Monday, October 23rd. equinet AG set a €112.00 ($131.76) price target on shares of Merck KGaA and gave the company a “buy” rating in a research report on Thursday, August 31st. Societe Generale set a €103.00 ($121.18) price target on shares of Merck KGaA and gave the company a “neutral” rating in a research report on Tuesday, September 5th. Goldman Sachs Group, Inc. (The) set a €105.00 ($123.53) price target on shares of Merck KGaA and gave the company a “neutral” rating in a research report on Wednesday, September 6th. Finally, Independent Research GmbH set a €105.00 ($123.53) price target on shares of Merck KGaA and gave the company a “neutral” rating in a research report on Monday, August 28th. Eleven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of €108.76 ($127.96).

Merck KGaA (MRK) opened at €89.60 ($105.41) on Thursday. Merck KGaA has a 12-month low of €89.21 ($104.95) and a 12-month high of €115.00 ($135.29).

TRADEMARK VIOLATION WARNING: “Merck KGaA (MRK) Given a €116.00 Price Target by Berenberg Bank Analysts” was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/11/23/merck-kgaa-mrk-given-a-116-00-price-target-by-berenberg-bank-analysts.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.